© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
Latest Conference Articles
Defining Oligometastatic Disease Vital to Support Interpretation of Breast Cancer Trial Results
June 7th 2021, 8:21pm
The definition of oligometastatic disease has continued to be shrouded in uncertainty due to the varying assessment criteria that exist at present during trial analyses.
New Agents Show Promise in HER2 Breast Cancer
June 7th 2021, 6:27pm
Margetuximab, trastuzumab deruxtecan, and tucatinib have all been approved in the past 2 years for the treatment of various subsets of patients with breast cancer.
Better Predictions of Detectable Tumor Cells Still Needed to Improve Outcomes for Patients With Resectable Non-Small Cell Lung Cancer
June 7th 2021, 5:23pm
Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses what is still needed to be investigated in the future following the phase 3 trial assessing nivolumab plus platinum-doublet chemotherapy as neoadjuvant treatment for resectable non-small cell lung cancer.
Nivolumab Plus Platinum-Doublet Chemotherapy for Resectable Non-Small Cell Lung Cancer May Improve Patient Quality of Life
June 7th 2021, 5:08pm
Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses what some of the most important findings were in regard to patient outcomes from the phase 3 trial assessing nivolumab plus platinum-doublet chemotherapy for resectable non-small cell lung cancer.
No Significant Signal in Adverse Events in Phase 3 Trial Assessing Nivolumab Plus Platinum-Doublet Chemotherapy for Resectable Non-Small Cell Lung Cancer
June 7th 2021, 3:27pm
Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses findings regarding adverse events during the phase 3 trial assessing nivolumab plus platinum-doublet chemotherapy as neoadjuvant treatment for resectable non-small cell lung cancer.
Assessing Future Treatment Options for Patients With Resectable Non-Small Cell Lung Cancer
June 7th 2021, 3:00pm
Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses what the findings of the phase 3 CheckMate 816 trial assessing nivolumab plus platinum-doublet chemotherapy as neoadjuvant treatment for patients with resectable non-small cell lung cancer may mean for future treatment options.
An Overview of the Phase 3 Trial Assessing Nivolumab Plus Platinum-doublet Chemotherapy for Resectable Non-Small Cell Lung Cancer
June 7th 2021, 2:54pm
Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses his presentation on surgical outcomes from the phase 3 CheckMate 816 trial assessing nivolumab plus platinum-doublet chemotherapy as neoadjuvant treatment for patients with resectable non-small cell lung cancer.
The Importance of the Assessment of Lutetium Lu 177 Dotatate for Advanced Midgut Neuroendocrine Tumors to the Field
June 6th 2021, 6:13pm
Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses the overall impact of the research assessing lutetium Lu 177 dotatate for midgut neuroendocrine tumors.
An Overview of Patients’ Quality of Life on Lutetium Lu 177 Dotatate for Advanced Midgut Neuroendocrine Tumors
June 6th 2021, 4:03pm
Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses patients reports of their quality of life while being treated with lutetium Lu 177 dotatate for midgut neuroendocrine tumors.
The Impact on the Treatment Landscape of Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma
June 6th 2021, 2:46pm
Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, explained how results from the phase 3 trial could change the treatment opportunities for patients with aRCC, as well as the treatment landscape more broadly.